Setting the Bar for Therapeutic Trials in Non–Small-Cell Lung Cancer: How Low Can We Go?

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping

(2014) Adrian G. Sacher et al.   JOURNAL OF CLINICAL ONCOLOGY

Right Answers, Wrong Questions in Clinical Research

(2014) R. I. Horwitz et al.   Science Translational Medicine

Overall survival should be the primary endpoint in clinical trials for advanced non-small cell lung cancer

(2013) P.K. Cheema et al.   Current Oncology

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

(2013) Jyoti D. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)

(2012) Corey J. Langer et al.   CANCER TREATMENT REVIEWS

Progression-Free Survival: Meaningful or Simply Measurable?

(2012) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY

A Historical Perspective on Clinical Trials Innovation and Leadership

(2011) David L. DeMets   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies

(2011) Marc Buyse et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies

(2011) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

Adaptive clinical trials in oncology

(2011) Donald A. Berry   Nature Reviews Clinical Oncology

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

(2010) J. C. Soria et al.   ANNALS OF ONCOLOGY

Raising the Bar of Efficacy for Drug Approval Requires an Understanding of Patient Diversity

(2010) Marc L. Berger et al.   JOURNAL OF CLINICAL ONCOLOGY

Demystify Statistical Significance--Time to Move on From the P Value to Bayesian Analysis

(2010) J. J. Lee   JNCI-Journal of the National Cancer Institute

When Are "Positive" Clinical Trials in Oncology Truly Positive?

(2010) A. Ocana et al.   JNCI-Journal of the National Cancer Institute

Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer

(2010) Katsuyuki Hotta et al.   Journal of Thoracic Oncology

Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval

(2009) Alberto Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question

(2009) T. Fojo et al.   JNCI-Journal of the National Cancer Institute

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

(2008) Cesare Gridelli et al.   Journal of Thoracic Oncology

Endpoints for Assessing Drug Activity in Clinical Trials

(2008) R. Pazdur   ONCOLOGIST